28 results on '"Delforge, Michel"'
Search Results
2. Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP‐EBMT study.
- Author
-
Gagelmann, Nico, Eikema, Dirk‐Jan, Koster, Linda, Netelenbos, Tanja, McDonald, Andrew, Stoppa, Anne‐Marie, Fenk, Roland, Anagnostopoulos, Achilles, van Gorkom, Gwendolyn, Deconinck, Eric, Bulabois, Claude‐Eric, Delforge, Michel, Bunjes, Donald, Arcese, William, Reményi, Péter, Itälä‐Remes, Maija, Thurner, Lorenz, Bolaman, Ali Zahit, Nabil, Yafour, and Lund, Johan
- Subjects
EXTRAMEDULLARY diseases ,MULTIPLE myeloma ,THALIDOMIDE ,DIAGNOSIS ,LENALIDOMIDE - Abstract
Background: No adequate data exist on the impact of multiple myeloma (MM) with extramedullary disease (EMD) after autograft and maintenance therapy. Methods: We identified 808 patients with newly diagnosed MM who received first autograft, of whom 107 had EMD (83 paraskeletal and 24 organ involvement), and who had been reported to the EBMT registry December 2018. Distribution according to type of involvement was similar between the treatment groups (p =.69). For EMD, 46 (40%) received thalidomide, 59 (51%) lenalidomide, and 11 (10%) bortezomib. Results: The median follow‐up from maintenance start was 44 months. Three‐year progression‐free survival (PFS) was 52% (48%–57%) for no EMD, 56% (44%–69%) for paraskeletal involvement, and 45% (22%–68%) for organ involvement (p =.146). Early PFS (within first year) appeared to be significantly worse for organ involvement (hazard ratio, 3.40), while no significant influence was found after first year from maintenance start. Three‐year overall survival (OS) was 81% (77%–84%), 88% (80%–96%), and 68% (47%–89%; p =.064), respectively. With thalidomide as reference, lenalidomide was significantly associated with better PFS and OS, whereas bortezomib appeared to improve outcome specifically in EMD. Conclusion: Lenalidomide maintenance is standard of care for MM without EMD, whereas extramedullary organ involvement remains a significant risk factor for worse outcome, especially for early events after maintenance start. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. P979: PATIENT‐REPORTED OUTCOMES FOR TECLISTAMAB VERSUS REAL‐WORLD PHYSICIAN’S CHOICE OF THERAPY IN THE LOCOMMOTION STUDY IN PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.
- Author
-
Moreau, Philippe, van de Donk, Niels W.C.J., Delforge, Michel, Einsele, Hermann, De Stefano, Valerio, Perrot, Aurore, Besemer, Britta, Pawlyn, Charlotte, Karlin, Lionel, Manier, Salomon, Leleu, Xavier, Thilakarathne, Pushpike, Diels, Joris, Gries, Katharine, Erler‐Yates, Nichola, van Nimwegen, Kirsten, Morano, Raúl, Strulev, Vadim, Haddad, Imene, and Kobos, Rachel
- Published
- 2023
- Full Text
- View/download PDF
4. P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE‐CEL) VERSUS STANDARD REGIMENS.
- Author
-
Delforge, Michel, Patel, Krina, Eliason, Laurie, Dhanda, Devender, Shi, Ling, Guo, Shien, Marshall, Thomas, Arnulf, Bertrand, Cavo, Michele, Nooka, Ajay, Manier, Salomon, Callander, Natalie, Giralt, Sergio, Einsele, Hermann, Ailawadhi, Sikander, Popa Mckiver, Mihaela, Cook, Mark, and Rodríguez‐Otero, Paula
- Published
- 2023
- Full Text
- View/download PDF
5. P904: LOCOMMOTION: A PROSPECTIVE, OBSERVATIONAL, MULTINATIONAL STUDY OF REAL‐LIFE CURRENT STANDARDS OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA– FINAL ANALYSIS AT 2‐YEAR FOLLOW‐UP.
- Author
-
Moreau, Philippe, Weisel, Katja, De Stefano, Valerio, Goldschmidt, Hartmut, Delforge, Michel, Mohty, Mohamad, Lindsey‐Hill, Joanne, Dytfeld, Dominik, Angelucci, Emanuele, Vincent, Laure, Perrot, Aurore, Benjamin, Reuben, van de Donk, Niels W.C.J., Ocio, Enrique, In‘t Groen‐Damen, Ester, Roccia, Tito, Schecter, Jordan, Haddad, Imene, Strulev, Vadim, and Mitchell, Lada
- Published
- 2023
- Full Text
- View/download PDF
6. Ultra‐low depth sequencing of plasma cell DNA for the detection of copy number aberrations in multiple myeloma.
- Author
-
Buedts, Lieselot, Smits, Sanne, Ameye, Geneviève, Lehnert, Stefan, Ding, Jia, Delforge, Michel, Vermeesch, Joris, Boeckx, Nancy, Tousseyn, Thomas, Michaux, Lucienne, Vandenberghe, Peter, and Dewaele, Barbara
- Published
- 2020
- Full Text
- View/download PDF
7. Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma.
- Author
-
Hájek, Roman, Delforge, Michel, Raab, Marc S., Schoen, Paul, DeCosta, Lucy, Spicka, Ivan, Radocha, Jakub, Pour, Ludek, Gonzalez‐McQuire, Sebastian, and Bouwmeester, Walter
- Subjects
- *
MULTIPLE myeloma , *MONOCLONAL gammopathies , *DISEASE progression , *ALGORITHMS - Abstract
Summary: Multiple myeloma (MM) is a malignancy with varying survival outcomes and drivers of disease progression. Existing MM staging tools were developed using data from newly diagnosed patients. As patient characteristics and disease‐related factors change between diagnosis and the initiation of second‐line (2L) treatment, an unmet need exists for a tool that can evaluate risk of death at first relapse. We have developed a risk stratification algorithm (RSA) using data from patients with MM who were at 2L. Hazard ratios for independent predictors of overall survival (OS) were derived from a Cox models, and individual patient scores were calculated for total risk. K‐adaptive partitioning for survival was used to stratify patients into groups based on their scores. Relative risk doubled with ascending risk group; median OSs for patients in group 1 (lowest risk)–4 (highest risk) were 61·6, 29·6, 14·2 and 5·9 months, respectively. Differences in OS between risk groups were significant. Similar stratification was observed when the RSA was applied to an external validation data set. In conclusion, we have developed a validated RSA that can quantify total risk, frailty risk and disease aggressiveness risk, and stratify patients with MM at 2L into groups with profoundly different survival expectations. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
8. Bortezomib‐based therapy for relapsed/refractory multiple myeloma in real‐world medical practice.
- Author
-
Terpos, Evangelos, Katodritou, Eirini, de la Rubia, Javier, Hungria, Vania, Hulin, Cyrille, Roussou, Maria, Delforge, Michel, Bries, Greet, Stoppa, Anne‐Marie, Aagesen, Jesper, Sargin, Deniz, Belch, Andrew, Ahlberg, Lucia, Diels, Joris, Olie, Robert A., Robinson, Jr, Don, Spencer, Mike, Potamianou, Anna, van de Velde, Helgi, and Dimopoulos, Meletios A.
- Subjects
BORTEZOMIB ,MULTIPLE myeloma treatment ,DEXAMETHASONE ,DRUG efficacy ,IMMUNOTHERAPY - Abstract
Abstract: Objective: The efficacy and safety of bortezomib‐based therapy for relapsed/refractory multiple myeloma (RRMM) in clinical trials may differ from the oncology practice experience. The electronic VELCADE
® OBservational Study was designed to prospectively evaluate bortezomib for multiple myeloma (MM) in real‐world medical practice. Method: Patients scheduled to receive intravenous bortezomib for MM were eligible. The primary objective was to evaluate clinical outcomes, including response, time to response, time to next therapy, treatment‐free interval, progression‐free survival (PFS), and overall survival (OS). Secondary objectives included safety and healthcare resource utilization. Results: In total, 873 patients with a median of two therapy lines prior to initiating bortezomib were included. The overall response rate (≥partial response) was 69%, including 37% complete response/near‐complete response. Median time to response was 1.8 months, median time to next therapy was 9.7 months, and median treatment‐free interval was 7.9 months. After 22.6 months’ median follow‐up, median PFS was 12.0 months and median OS was 36.1 months. The most common adverse events (AEs) were neuropathy not otherwise specified (19%), diarrhea NOS, and thrombocytopenia (each 17%); 230 (26%) patients discontinued bortezomib due to AEs. Of 689 (79%) patients without baseline peripheral neuropathy (PN), the rate of new‐onset any‐grade PN increased to 51% (12% grade 3/4) by cycle 8. Overall, 244 (28%) patients were hospitalized, 372 (43%) attended an outpatient visit, and 341 (39%) underwent a diagnostic/therapeutic procedure during bortezomib treatment. Conclusion: These prospective real‐world data demonstrate the effectiveness and safety of bortezomib‐based therapy for RRMM and confirm high response rates and long OS for this population. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
9. PB2114: BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD OBSERVATIONAL STUDY UPDATE.
- Author
-
Hultcrantz, Malin, Kleinman, David, Vij, Ravi, Escalante, Fernando, Delforge, Michel, Kotowsky, Nirali, Bitetti, Jacopo, Boytsov, Natalie, Camadoo-O'byrne, Leena, Happ, Lindsey Powers, Rohman, Mujib, Germain, Guillaume, Duh, Mei Sheng, Laliberté, François, Mahendran, Malena, Urosevic, Ana, and Lee, Hans C.
- Published
- 2023
- Full Text
- View/download PDF
10. P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).
- Author
-
Sidana, Surbhi, Moreau, Philippe, Garfall, Alfred, Bhutani, Manisha, Oriol, Albert, Nooka, Ajay, Martin, Tom, Rosiñol Dachs, Laura, Mateos, Maria-Victoria, Bahlis, Nizar J, Popat, Rakesh, Besemer, Britta, Martinez-Lopez, Joaquín, Krishnan, Amrita, Delforge, Michel, Trancucci, Danielle, Verona, Raluca, Stephenson, Tara, Chastain, Katherine, and van de Donk, Niels W.C.J.
- Published
- 2023
- Full Text
- View/download PDF
11. S195: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): A KARMMA-3 ANALYSIS IN HIGH-RISK SUBGROUPS.
- Author
-
Patel, Krina, Rodríguez-Otero, Paula, Manier, Salomon, Baz, Rachid, Raab, Marc S., Cavo, Michele, Callander, Natalie, Costa, Luciano, Moreau, Philippe, Solomon, Scott, Chen, Christine, Raje, Noopur, Scheid, Christof, Delforge, Michel, Larsen, Jeremy, Pabst, Thomas, Suzuki, Kenshi, Truppel-Hartmann, Anna, Yang, Zhihong, and Piasecki, Julia
- Published
- 2023
- Full Text
- View/download PDF
12. Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.
- Author
-
Jurczyszyn, Artur, Radocha, Jakub, Davila, Julio, Fiala, Mark A., Gozzetti, Alessandro, Grząśko, Norbert, Robak, Pawel, Hus, Iwona, Waszczuk-Gajda, Anna, Guzicka-Kazimierczak, Renata, Atilla, Erden, Mele, Giuseppe, Sawicki, Waldemar, Jayabalan, David S., Charliński, Grzegorz, Szabo, Agoston G., Hajek, Roman, Delforge, Michel, Kopacz, Agnieszka, and Fantl, Dorotea
- Subjects
RETROSPECTIVE studies ,PLASMA cell leukemia ,STEM cell transplantation ,MULTIVARIATE analysis ,BLOOD platelets - Abstract
We report a multicentre retrospective study that analysed clinical characteristics and outcomes in 117 patients with primary plasma cell leukaemia (pPCL) treated at the participating institutions between January 2006 and December 2016. The median age at the time of pPCL diagnosis was 61 years. Ninety-eight patients were treated with novel agents, with an overall response rate of 78%. Fifty-five patients (64%) patients underwent upfront autologous stem cell transplantation (ASCT). The median followup time was 50 months (95% confidence interval [CI] 33; 76), with a median overall survival (OS) for the entire group of 23 months (95% CI 15; 34). The median OS time in patients who underwent upfront ASCT was 35 months (95% CI 24·3; 46) as compared to 13 months (95% CI 6&3183;3; 35·8) in patients who did not receive ASCT (P = 0&3183;001). Multivariate analyses identified age ≥60 years, platelet count ≤100 9 109/l and peripheral blood plasma cell count ≥20 9 109/l as independent predictors of worse survival. The median OS in patients with 0, 1 or 2–3 of these risk factors was 46, 27 and 12 months, respectively (P < 0·001). Our findings support the use of novel agents and ASCT as frontline treatment in patients with pPCL. The constructed prognostic score should be independently validated. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
13. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.
- Author
-
Moreau, Philippe, Dimopoulos, Meletios A., Richardson, Paul G., Siegel, David S., Cavo, Michele, Corradini, Paolo, Weisel, Katja, Delforge, Michel, O'Gorman, Peter, Song, Kevin, Chen, Christine, Bahlis, Nizar, Oriol, Albert, Hansson, Markus, Kaiser, Martin, Anttila, Pekka, Raymakers, Reinier, Joao, Cristina, Cook, Gordon, and Sternas, Lars
- Subjects
ADVERSE health care events ,THERAPEUTIC complications ,MULTIPLE myeloma treatment ,DEXAMETHASONE ,HEALTH of patients - Abstract
Objectives Heavily pretreated patients with relapsed and refractory multiple myeloma are susceptible to treatment-related adverse events (AEs). Managing AEs are important to ensure patients continue therapy long enough to receive the best clinical benefit. Data from the MM-002, MM-003, and MM-010 trials were pooled to further characterize the safety profile of pomalidomide plus low-dose dexamethasone and AE management. Methods This analysis included 1088 patients who received ≥ 2 prior therapies, including lenalidomide and bortezomib, and progressed ≤ 60 days of last therapy. Patients received 28-day cycles of pomalidomide 4 mg/day on days 1-21 and low-dose dexamethasone 40 mg (20 mg if aged > 75 years) weekly until disease progression or unacceptable toxicity. Thromboprophylaxis was required. Results The most common grade 3/4 AEs were neutropenia (56.2%), anemia (32.3%), and thrombocytopenia (25.8%), which occurred within the first few cycles of treatment. Grade 3/4 infections occurred in 33.7% patients, of whom 13.9% had pneumonia, and 40.3% had neutropenia. Pomalidomide dose reductions or interruptions were reported in 24.2% and 66.0% of patients, respectively. AEs were managed by dose modifications and/or supportive care. Conclusions Pomalidomide plus low-dose dexamethasone showed an acceptable safety profile, and AEs were well managed according to study protocols and established guidelines. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
14. Multiple myeloma: patient outcomes in real-world practice.
- Author
-
Yong, Kwee, Delforge, Michel, Driessen, Christoph, Fink, Leah, Flinois, Alain, Gonzalez‐McQuire, Sebastian, Safaei, Reza, Karlin, Lionel, Mateos, Maria‐Victoria, Raab, Marc S., Schoen, Paul, and Cavo, Michele
- Subjects
- *
MULTIPLE myeloma , *DISEASE progression , *PROGRESSION-free survival , *DISEASE remission , *HEMATOLOGY - Abstract
With increasing number of therapies available for the treatment of multiple myeloma, it is timely to examine the course of patients' journeys. We investigated patient characteristics, treatment durations and outcomes, and symptom burden across the treatment pathway in Belgium, France, Germany, Italy, Spain, Switzerland and the UK. In total, 435 physicians retrospectively reviewed 4997 patient charts. Profiles of patients diagnosed with multiple myeloma during the last 12 months were similar across countries; bone pain was the most common presentation. Median duration of first-line therapy was 6 months, followed by a median treatment-free interval of 10 months; both these decreased with increasing lines of therapy, as did time to progression. Depth of response, as assessed by the treating physician, also decreased with each additional line of therapy: 74% of patients achieved at least a very good partial response at first line, compared with only 11% at fifth line. Deeper responses were associated with longer time to progression, although these were physician-judged. Toxicities and co-morbidities increased with later treatment lines, and were more likely to have led to discontinuation of treatment. These real-world data provide an insight into patient outcomes and treatment decisions being made in clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
15. Multiple myeloma: practice patterns across Europe.
- Author
-
Raab, Marc S., Cavo, Michele, Delforge, Michel, Driessen, Christoph, Fink, Leah, Flinois, Alain, Gonzalez‐McQuire, Sebastian, Safaei, Reza, Karlin, Lionel, Mateos, Maria‐Victoria, Schoen, Paul, and Yong, Kwee
- Subjects
MULTIPLE myeloma treatment ,ANTINEOPLASTIC agents ,BORTEZOMIB ,ONCOLOGY ,MEDICAL practice ,THERAPEUTICS - Abstract
Real-world data describing management of patients with multiple myeloma are limited. A European (Belgium, France, Germany, Italy, Spain, Switzerland, UK) observational chart review was conducted to address this. Physicians completed questionnaires for every patient seen during a 2-4-week observation period, regardless of treatment status. A total of 435 physicians completed 7635 cross-sectional chart reviews. Overall, 47% of patients were undergoing anti-tumour drug treatment, 42% had previously received ≥1 line of treatment and 12% had never received anti-tumour drug treatment. Of the patients treated by oncologists, onco-haematologists or internists, 95% received, or were expected to receive, at least one line of anti-tumour drug treatment, 61% received ≥2 lines of therapy and 38% received ≥3 lines. Except in the UK, the most commonly used induction therapies contained bortezomib (48%); lenalidomide was the most commonly used first-line maintenance therapy (45%) and second- and third-line agent overall (60% and 52% of patients at those lines, respectively). Bortezomib retreatment was used in 47% of patients who received it first line. Treatment patterns became more diverse with subsequent treatment lines. This study provides insight into real-world treatment patterns in Europe. While treatment practices are broadly similar across countries, some notable differences in the agents used exist. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
16. Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice.
- Author
-
Delforge, Michel, Vekemans, Marie-Christiane, Depaus, Julien, Meuleman, Nathalie, Van de Velde, Ann, Vande Broek, Isabelle, Vandervennet, Sophie, Van Hoorenbeeck, Sandra, Moorkens, Evelien, Strens, Danielle, Diels, Joris, Ghilotti, Francesca, Haefliger, Benjamin, Dalhuisen, Sander, Deraedt, William, and Anguille, Sébastien
- Published
- 2022
- Full Text
- View/download PDF
17. Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone.
- Author
-
Morgan, Gareth, Palumbo, Antonio, Dhanasiri, Sujith, Lee, Dawn, Weisel, Katja, Facon, Thierry, Delforge, Michel, Oriol, Albert, Zaki, Mohamed, Yu, Xin, Sternas, Lars, Jacques, Christian, Akehurst, Ron, Offner, Fritz, and Dimopoulos, Meletios A.
- Subjects
MULTIPLE myeloma treatment ,DEXAMETHASONE ,THALIDOMIDE ,CANCER relapse ,SURVIVAL analysis (Biometry) ,COMBINATION drug therapy ,DOSE-effect relationship in pharmacology ,THERAPEUTICS ,PREVENTION - Abstract
In the phase III MM-003 trial, pomalidomide plus low-dose dexamethasone ( POM+Lo DEX) improved overall survival ( OS) versus high-dose dexamethasone (Hi DEX) in 455 patients with relapsed and refractory multiple myeloma ( RRMM) after treatment with bortezomib and lenalidomide. Here, a two-stage Weibull method was used to adjust for the crossover of patients in the Hi DEX arm to pomalidomide-based therapy. The adjusted difference in median OS between patients in the POM+Lo DEX and Hi DEX arms was 7·0 months (12·7 vs. 5·7 months, respectively). These findings provide important evidence for understanding the clinical efficacy of pomalidomide on OS benefits seen in RRMM patients. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
18. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.
- Author
-
Delforge, Michel, Dhawan, Ravinder, Robinson, Don, Meunier, Juliette, Regnault, Antoine, Esseltine, Dixie-Lee, Cakana, Andrew, Velde, Helgi, Richardson, Paul G., and San Miguel, Jesús F.
- Subjects
- *
DISEASES in older people , *QUALITY of life , *MULTIPLE myeloma diagnosis , *PREDNISONE , *HEALTH status indicators , *MULTIVARIATE analysis - Abstract
Objectives The phase 3 VISTA study ( NCT00111319) in transplant-ineligible myeloma patients demonstrated superior efficacy with bortezomib-melphalan-prednisone ( VMP; nine 6-wk cycles) vs. melphalan-prednisone ( MP) but also increased toxicity. Health-related quality of life ( HRQoL; exploratory endpoint) was evaluated using the European Organization for Research and Treatment of Cancer ( EORTC) Quality of Life Questionnaire ( QLQ-C30). The phase 3 VISTA study ( NCT00111319) in transplant-ineligible myeloma patients demonstrated superior efficacy with bortezomib-melphalan-prednisone ( VMP; nine 6-wk cycles) vs. melphalan-prednisone ( MP) but also increased toxicity. Health-related quality of life ( HRQoL; exploratory endpoint) was evaluated using the European Organization for Research and Treatment of Cancer ( EORTC) Quality of Life Questionnaire ( QLQ-C30). Methods EORTC QLQ-C30 was administered at screening, on day 1 of each cycle, at the end-of-treatment visit, and every 8 wk until progression. EORTC QLQ-C30 scores were evaluated among patients with a valid baseline and at least one post-baseline HRQoL assessment. Results At baseline, domain scores were similar between arms. By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP. From cycle 5 onwards, improvements relative to baseline/ MP were observed for all domains with VMP. Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms. Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response ( CR). Multivariate analysis showed a significant impact of duration of response/ CR on improving global health status, pain, and appetite loss scores. Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity. Conclusions These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities. However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
19. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
- Author
-
Delforge, Michel, Terpos, Evangelos, Richardson, Paul G., Shpilberg, Ofer, Khuageva, Nuriet K., Schlag, Rudolf, Dimopoulos, Meletios A., Kropff, Martin, Spicka, Ivan, Petrucci, Maria T., Samoilova, Olga S., Mateos, Maria-Victoria, Magen-Nativ, Hila, Goldschmidt, Hartmut, Esseltine, Dixie-Lee, Ricci, Deborah S., Liu, Kevin, Deraedt, William, Cakana, Andrew, and van de Velde, Helgi
- Subjects
- *
BONE diseases , *MULTIPLE myeloma treatment , *PREDNISONE , *ALKALINE phosphatase , *DIPHOSPHONATES - Abstract
Bone disease is a key presenting feature of myeloma. This post hoc analysis of the phase III VISTA trial of bortezomib plus melphalan-prednisone (VMP) vs. MP in previously untreated myeloma patients assessed clinical bone disease events and changes in alkaline phosphatase (ALP), a marker for osteoblast activation, and serum Dickkopf-1 (DKK-1), an inhibitor of osteoblast differentiation, during treatment. Patients received nine 6-wk cycles of VMP (bortezomib 1.3 mg/m, days 1, 4, 8, 11, 22, 25, 29, 32, cycles 1-4, days 1, 8, 22, 29, cycles 5-9, plus melphalan 9 mg/m and prednisone 60 mg/m, days 1-4, cycles 1-9; N = 344) or MP alone ( N = 338). Rates of bisphosphonates use during treatment (73% vs. 82%), progression because of worsening bone disease (3% vs. 11%), and requirement for subsequent radiotherapy (3% vs. 8%) were lower with VMP vs. MP. Median maximum ALP increase was significantly higher with VMP vs. MP overall (49.7% vs. 30.3%, P = 0.029), and higher by response group (complete response [CR]: 68.7% vs. 43.9%; partial response [PR]: 41.5% vs. 31.2%). Greater maximum ALP increase was strongly associated with achievement of CR ( P ≤ 0.0001) and CR/PR ( P ≤ 0.01). Median DKK-1 decreased with VMP by 694.4 pg/mL and increased with MP by 1273.3 pg/mL from baseline to day 4 ( P = 0.0069). Available radiologic data revealed evidence of bone healing in 6/11 VMP-treated patients, who achieved best responses of three CR, one PR, and two stable disease. These results suggest a positive effect of bortezomib on bone metabolism and potentially bone healing in myeloma. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
20. Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study.
- Author
-
VAN CALSTEREN, KRISTEL, VERBESSELT, RENÉ, OTTEVANGER, NELLEKE, HALASKA, MICHAEL, HEYNS, LIESBETH, VAN BREE, RIETA, DE BRUIJN, ERNST, CHAI, DANIEL, DELFORGE, MICHEL, NOENS, LUCIEN, RENARD, VINCENT, WITTEVEEN, ELS, ROB, LUKAS, DE HOON, JAN, and AMANT, FRÉDÉRIC
- Subjects
GYNECOLOGY ,PREGNANCY ,PHARMACOKINETICS ,DRUG therapy ,BABOONS as laboratory animals - Abstract
Objective. To determine the impact of physiologic changes of pregnancy on pharmacokinetics of chemotherapeutic agents. Design. A preclinical and a clinical case-control trial. Setting. Institute of Primate Research Nairobi and collaborating hospitals in Belgium, the Netherlands and Czech Republic. Population. Pregnant and nonpregnant women and baboons receiving chemotherapy. Methods. Chemotherapy pharmacokinetics was compared between the pregnant and nonpregnant state. Standard-dosed chemotherapy regimens were administered in pregnant and nonpregnant baboons/women, followed by serial blood samplings. Drug plasma levels were determined using high performance liquid chromatography and atomic absorption spectrometry. Main outcome measures. Area under the curve (AUC), maximal plasma concentration, terminal elimination half-life, clearance and distribution volume of each drug in pregnant and nonpregnant state. Results. Intraindividual comparative pharmacokinetic data were obtained for doxorubicin and paclitaxel/platinum in three and two baboons, respectively. In the clinical trial, two patients were exposed to doxorubicin and one patient was exposed to paclitaxel/platinum during and after pregnancy. Furthermore, a pooled analysis was performed based on 16 cycles of pregnant and 11 cycles of nonpregnant women. Numbers of pregnant/nonpregnant patients were 5/2, 7/5, 4/4 and 2/2 for paclitaxel, doxorubicin, epirubicin and platinum, respectively. For all drugs tested in the preclinical and clinical study, a decreased AUC and maximal plasma concentration and an increased distribution volume and clearance were observed in pregnancy. Conclusions. Although numbers were too small for statistical significance, pregnancy-associated physiologic alterations appear to lead to a decrease in plasma exposure of chemotherapeutic drugs. The importance of long-term follow-up of women treated with chemotherapy during pregnancy is underscored. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
21. The t(14;20)(q32;q12): a rare cytogenetic change in multiple myeloma associated with poor outcome.
- Author
-
Vekemans, Marie-Christiane, Lemmens, Heidi, Delforge, Michel, Doyen, Chantal, Pierre, Pascal, Demuynck, Hilde, Bries, Greet, Lemmens, Jan, Meeus, Peter, Straetmans, Nicole, Bauwens, Deborah, Vidrequin, Sébastien, Rack, Katrina, Vandenberghe, Peter, Wlodarska, Iwona, and Michaux, Lucienne
- Subjects
LETTERS to the editor ,MULTIPLE myeloma - Abstract
A letter to the editor is presented regarding the cytogenetic status in multiple myeloma (MM).
- Published
- 2010
- Full Text
- View/download PDF
22. Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival.
- Author
-
de Witte, Theo, Brand, Ronald, van Biezen, Anja, Mufti, Ghulam, Ruutu, Tapani, Finke, Jürgen, von dem Borne, Peter, Vitek, Antonin, Delforge, Michel, Alessandrino, Paolo, Harlahakis, Nicolas, Russell, Nigel, Martino, Roberto, Verdonck, Leo, Kröger, Nicholas, and Niederwieser, Dietger
- Subjects
STEM cell transplantation ,HLA histocompatibility antigens ,APLASTIC anemia ,ANEMIA diagnosis ,CELLULAR therapy - Abstract
Allogeneic stem cell transplantation (alloSCT) for patients with refractory anaemia may result in a 50% event-free survival, but the high non-relapse mortality (NRM) precludes a general application of this therapeutic modality. This study evaluated the impact of various pre-transplant variables, including disease duration, intensity of the conditioning regimen, type of donor and year of transplantation on outcome. The study population consisted of 374 patients; 244 were transplanted from human leucocyte antigen (HLA)-identical siblings and 130 patients from matched unrelated donors. The median age was 39 years. One hundred and two patients were transplanted after reduced intensity conditioning (RIC). The overall 4-year survival was 52%. The 4-year survival of patients transplanted with HLA-identical sibling donors and matched unrelated donors was 52% and 50%, respectively. Multivariate analysis showed an improved survival ( P = 0·05) and a lower NRM ( P = 0·02) when the transplantation was performed in recent years. Increasing age, and disease duration of >12 months were associated with inferior survival. RIC resulted in a similar survival despite an increased relapse risk ( P = 0·02). This improved outcome permits alloSCT in patients older than 50 years of age, even with the use of matched unrelated donors. AlloSCT should be preferentially performed early after diagnosis after careful analysis of prognostic variables. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
23. Diagnostic performance of serum free light chain measurement in patients suspected of a monoclonal B-cell disorder.
- Author
-
Vermeersch, Pieter, Van Hoovels, Lieve, Delforge, Michel, Mariën, Godelieve, and Bossuyt, Xavier
- Subjects
B cells ,MONOCLONAL gammopathies ,SERUM ,DIAGNOSIS ,PLASMACYTOMA ,DISEASES - Abstract
The present study aimed to determine the diagnostic performance of different testing strategies to diagnose malignant B-cell disorder or monoclonal gammopathy of unknown significance (MGUS). Sensitivity and specificity were determined in 833 consecutive patients investigated for a monoclonal gammopathy. Serum protein electrophoresis (PE), serum κ/ λ free light chain (FLC) ratio, and serum and urine immunofixation electrophoresis (IFE) were performed in all patients. Twenty-eight patients were diagnosed with a malignant plasma cell disorder, 25 with B-cell non-Hodgkin lymphoma and 156 with MGUS. Serum PE (with follow-up IFE) plus FLC had a sensitivity of 82·3% and a specificity of 96·8% and missed one plasmacytoma and 23 patients with MGUS. Serum IFE plus urine IFE had a sensitivity of 92·3% and a specificity of 100% and missed two MGUS patients. Serum IFE plus FLC had a sensitivity of 93·8% and a specificity of 96·8% and missed one MGUS patient. Serum PE plus FLC had a significantly lower sensitivity than serum IFE plus FLC or serum IFE plus urine IFE for the diagnosis of MGUS. The sensitivity of serum IFE plus FLC was comparable to the sensitivity of serum IFE plus urine IFE. The specificity of serum IFE plus FLC, however, was lower than the specificity of serum IFE plus urine IFE. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
24. Patients with high-risk myelodysplastic syndrome can have polyclonal or clonal haemopoiesis in complete haematological remission.
- Author
-
Delforge, Michel, Demuynck, Hilde, Verhoef, Gregor, Vandenberghe, Peter, ZachÉE, Pierre, Maertens, Johan, Van Duppen, Viktor, Boogaerts, Marc A., and Boogaerts
- Subjects
- *
BONE marrow cells , *MYELODYSPLASTIC syndromes - Abstract
The clonality of mature peripheral blood-derived myeloid and lymphoid cells and bone marrow haemopoietic progenitors from 18 females with myelodysplasia (MDS) (five refractory anaemia, RA; one RA with ringed sideroblasts, RARS; three chronic myelomonocytic leukaemia, CMML; four RA with excess of blasts, RAEB; five RAEB in transformation, RAEB-t) was studied by X-chromosome inactivation analysis. Using the human androgen-receptor (HUMARA) assay, we analysed the clonal patterns of highly purified immature CD34+38- and committed CD34+38+ marrow-derived progenitors, and CD16+14- granulocytes, CD14+ monocytes, CD3+ T and CD19+ B lymphocytes from peripheral blood. In high-risk patients (RAEB, RAEB-t), clonality analysis was performed before and after intensive remission-induction treatment. All patients, except one with RA, had predominance of a single clone in their granulocytes and monocytes. The same clonal pattern was found in CD34+ progenitor cells. In contrast, CD3+ T lymphocytes were polyclonal or oligoclonal in 14/18 patients. X-chromosome inactivation patterns of CD19+ B cells were highly concordant with CD3+ T cells except for two patients (one RA, one CMML) with monoclonal B and polyclonal T lymphocytes, therefore suggesting a clonal mutation in a progenitor common to the myeloid and B-lymphoid lineages or the coexistence of MDS and a B-cell disorder in these particular patients. After high-dose non-myeloablative chemotherapy, polyclonal haemopoiesis was reinstalled in the mature myeloid cells and immature and committed marrow progenitors in three of four patients achieving complete haematological remission. Therefore we conclude that most haematological remissions in MDS are associated with restoration of polyclonal haemopoiesis. [ABSTRACT FROM AUTHOR]
- Published
- 1998
- Full Text
- View/download PDF
25. Comparative study of peripheral blood progenitor cell collection in patients with multiple myeloma after single-dose cyclophosphamide combined with rhGM-CSF or rhG-CSF.
- Author
-
DEMUYNCK, HILDE, DELFORGE, MICHEL, VERHOEF, GREGOR, ZACHEE, PIERRE, VANDENBERGHE, PETER, and BOOGAERTS, MARC
- Published
- 1995
- Full Text
- View/download PDF
26. Bortezomib retreatment for relapsed and refractory multiple myeloma in real‐world clinical practice.
- Author
-
Hulin, Cyrille, Rubia, Javier, Dimopoulos, Meletios A., Terpos, Evangelos, Katodritou, Eirini, Hungria, Vania, De Samblanx, Hadewijch, Stoppa, Anne‐Marie, Aagesen, Jesper, Sargin, Deniz, Sioni, Anastasia, Belch, Andrew, Diels, Joris, Olie, Robert A., Robinson, Don, Potamianou, Anna, Velde, Helgi, and Delforge, Michel
- Subjects
BORTEZOMIB ,MULTIPLE myeloma treatment ,ADVERSE health care events - Abstract
Aims: Studies have shown that bortezomib retreatment is effective in relapsed/refractory multiple myeloma (MM). The observational, prospective electronic VELCADE® OBservational Study (eVOBS) study assessed bortezomib‐based therapies for patients with MM in everyday practice. Here, we report on those patients receiving retreatment with bortezomib. Methods: Consenting adults scheduled to receive bortezomib for MM were enrolled at 162 sites across Europe, Canada, Brazil, Russia, and Turkey between 2006 and 2010. Retrospective data on prior therapies and prospective observational data after bortezomib initiation were captured electronically at baseline, after every bortezomib cycle, and every 12 weeks after discontinuation or progression. Investigator‐assessed responses and adverse events (AEs) were evaluated. Results: Ninety‐six of 873 patients enrolled to eVOBS received bortezomib as first retreatment for progressive disease during the prospective observation period. Median age was 62 years, 53% were male, and median number of prior therapies at retreatment was 4. Overall, 41% of patients initiated bortezomib retreatment in combination with dexamethasone, 16% in combination with lenalidomide, and 21% received monotherapy. Rate of partial response or better (≥PR) was 75% at initial bortezomib therapy, including 44% complete response (CR)/near CR (nCR); at retreatment, ≥PR rate was 46%, including 15% CR/nCR. Median progression‐free survival was 11.4 months (95% confidence interval [CI]: 9.1‐12.7) from start of initial bortezomib treatment and 6.4 months (95% CI: 4.4‐7.2) from start of retreatment. Median overall survival from start of retreatment was 17.6 months (95% CI: 14.4‐23.5). Of the 96 patients retreated with bortezomib, 77% reported an AE. Peripheral neuropathy during bortezomib retreatment occurred in 49% of patients, including 10% grade 3/4. Conclusion: These data suggest that retreatment with bortezomib is a feasible option for patients with relapsed/refractory MM. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
27. Monocytes from patients with myelodysplastic syndromes are more resistant to inhibition by thalidomide.
- Author
-
Meers, Stef, Boon, Louis, Verhoef, Gregor, and Delforge, Michel
- Published
- 2009
- Full Text
- View/download PDF
28. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma.
- Author
-
Goldman-Mazur S, Jurczyszyn A, Castillo JJ, Waszczuk-Gajda A, Grząśko N, Radocha J, Bittrich M, Kortüm KM, Gozzetti A, Usnarska-Zubkiewicz L, Davila Valls J, Jayabalan DS, Niesvizky R, Kelman J, Coriu D, Rosiñol L, Szukalski Ł, González-Calle V, Mateos MV, Jamroziak K, Hus I, Avivi I, Cohen Y, Suska A, Chappell A, Madduri D, Chhabra S, Kleman A, Hari P, Delforge M, Robak P, Gentile M, Kozłowska I, Goldberg SL, Czepiel J, Silbermann R, Olszewski AJ, Barth P, Mikala G, Chim CS, Długosz-Danecka M, Grosicki S, and Vesole DH
- Subjects
- Female, Humans, Male, Middle Aged, Multiple Myeloma mortality, Progression-Free Survival, Retrospective Studies, Translocation, Genetic, Multiple Myeloma genetics
- Abstract
The t(14;16) translocation, found in 3%-5% of newly diagnosed (ND) multiple myeloma (MM), has been associated with adverse outcomes. However, the studies establishing the characteristics of t(14;16) included solely small cohorts. The goal of the current international, multicenter (n = 25 centers), retrospective study was to describe the characteristics and outcomes of t(14;16) patients in a large, real-world cohort (n = 223). A substantial fraction of patients had renal impairment (24%) and hemoglobin <10 g/dL (56%) on initial presentation. Combined therapy of both immunomodulatory drug and proteasome inhibitor (PI) in the first line was used in 35% of patients. Autologous stem cell transplantation was performed in 42% of patients. With a median follow up of 4.1 years (95% CI 3.7-18.7), the median progression-free survival (PFS) and overall survival (OS) from first line therapy were 2.1 years (95% CI 1.5-2.4) and 4.1 years (95% CI 3.3-5.5), respectively. Worse OS was predicted by age > 60 years (HR = 1.65, 95% CI [1.05-2.58]), as well as revised International Scoring System (R-ISS) 3 (vs R-ISS 2; HR = 2.59, 95% CI [1.59-4.24]). In conclusion, based on the largest reported cohort of t(14;16) patients, quarter of this subset of MM patients initially presents with renal failure, while older age and the R-ISS 3 predict poor survival., (© 2020 Wiley Periodicals, Inc.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.